3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Glioma
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
14
fludarabine
12
fludarabine phosphate
8
Melphalan
8
Brentuximab Vedotin
8
Whole-Body Irradiation
7
Mycophenolic Acid
7
Busulfan
7
Rituximab
6
Tacrolimus
5
Lenalidomide
4
Etoposide
4
isatuximab
3
Sirolimus
3
Mesna
3
Granulocyte Colony-Stimulating Factor
3
Dexamethasone
3
pembrolizumab
2
nilotinib
2
dacetuzumab
2
Vincristine
2
Thiotepa
2
Sugars
2
Stem Cell Transplantation
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Ondansetron
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Diseases
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled